Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival

Leuk Res. 2013 Sep;37(9):1094-9. doi: 10.1016/j.leukres.2013.06.022. Epub 2013 Jul 9.

Abstract

The goal of the study was to investigate the levels of interleukin-27 (IL-27) and IL-17 in bone marrow (BM) and peripheral blood (PB) of multiple myeloma (MM). The levels of IL-27 and IL-17 were determined in MM patients and controls using ELISA. The results showed a decreased IL-27 and elevated IL-17 level in MM patients and a negative association of IL-27 with IL-17. The ratio of IL-27:IL-17 in BM of newly diagnosed MM was significantly decreased and correlated with the progression of disease. Multivariate analysis showed that a higher ratio of IL-27:IL-17 in BM was associated with a superior progression-free survival (HR=0.160; 95% CI: 0.058-0.443; p<0.001). Our results suggest that there might be a possible competitive role of IL-27 and IL-17 in MM.

Keywords: Interleukin-17; Interleukin-27; Multiple myeloma; Progression-free survival.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Bone Marrow / metabolism*
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-17 / metabolism*
  • Interleukins / metabolism*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / mortality*
  • Neoplasm Staging
  • Prognosis
  • Remission Induction
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Interleukin-17
  • Interleukins
  • MYDGF protein, human